Genomic Health, Inc.
GHDX
GHDX was delisted on the 7th of November, 2019.
124 hedge funds and large institutions have $1.01B invested in Genomic Health, Inc. in 2017 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 59 increasing their positions, 37 reducing their positions, and 6 closing their positions.
59% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 37
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
4% more capital invested
Capital invested by funds: $968M → $1.01B (+$41.9M)
0% more funds holding
Funds holding: 124 → 124 (0)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$6.43M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.37M |
| 3 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$2.86M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$2.62M |
| 5 |
Renaissance Technologies
New York
|
+$2.54M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CWAM
Columbia Wanger Asset Management
Chicago,
Illinois
|
-$5.46M |
| 2 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
-$4.74M |
| 3 |
Millennium Management
New York
|
-$4.65M |
| 4 |
Mitsubishi UFJ Trust & Banking
Tokyo,
Japan
|
-$4.04M |
| 5 |
Two Sigma Investments
New York
|
-$3.11M |
GHDX Hedge Fund Activity: Q2 2017 in Review
124 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Genomic Health, Inc. (GHDX) for Q2 2017, worth a combined $1.01B — up 4.3% from $968M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new GHDX positions and 6 closed out — a net gain of 1 holder — while 59 added to existing stakes and 37 trimmed.
The largest buyer was Invesco, opening a new position worth an estimated $6.43M. The largest seller was Columbia Wanger Asset Management, cutting an estimated $5.46M.
- 124 institutional investors held Genomic Health, Inc. (GHDX) as of Q2 2017, unchanged from Q1 2017.
- Funds reported $1.01B of Genomic Health, Inc. stock for Q2 2017, up 4.3% quarter-over-quarter.
- 7 funds opened new Genomic Health, Inc. positions in Q2 2017 and 6 closed out, a net change of +1 holder.
- The largest Genomic Health, Inc. buyer in Q2 2017 was Invesco, an estimated $6.43M added.
- The largest Genomic Health, Inc. seller in Q2 2017 was Columbia Wanger Asset Management, an estimated $5.46M sold.
Based on aggregated 13F filings for Q2 2017.